Palindromic carbazole derivatives: unveiling their antiproliferative effect via topoisomerase II catalytic inhibition and apoptosis induction

References

• Upadhyay A. Cancer: an unknown territory; rethinking before going ahead. Genes Dis. 2021;8(5):655–661.
   PubMed Web of Science ®Google Scholar
• Berben L, Floris G, Wildiers H, Hatse S. Cancer and aging: two tightly interconnected biological processes. Cancers. 2021;13(6):1400.
   PubMed Web of Science ®Google Scholar
• Cancer; 2023 [accessed 2023 Jan 31]. https://www.who.int/health-topics/cancer#tab=tab_1.
   Google Scholar
• Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, Bashir AH, Mohammed OY, Elhassan GO, Harguindey S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1):71.
   PubMed Web of Science ®Google Scholar
• Tsutsumi LS, Gündisch D, Sun D. Carbazole scaffold in medicinal chemistry and natural products: a review from 2010–2015. Curr Top Med Chem. 2016;16(11):1290–1313.
   PubMed Web of Science ®Google Scholar
• Lin W, Wang Y, Lin S, Li C, Zhou C, Wang S, Huang H, Liu P, Ye G, Shen X. Induction of cell cycle arrest by the carbazole alkaloid Clauszoline-I from Clausena vestita D. D. Tao via inhibition of the PKCδ phosphorylation. Eur J Med Chem. 2012;47(1):214–220.
   PubMedGoogle Scholar
• Dias N, Jacquemard U, Baldeyrou B, Tardy C, Lansiaux A, Colson P, Tanious F, Wilson WD, Routier S, Mérour JY, et al. Targeting DNA with novel diphenylcarbazoles. Biochemistry. 2004;43(48):15169–15178.
   PubMed Web of Science ®Google Scholar
• Zembower DE, Xie Y, Koohang A, Kuffel MJ, Ames MM, Zhou Y, Mishra R, Mar AA, Flavin MT, Xu ZQ. Methylenedioxy- and ethylenedioxy-fused indolocarbazoles: potent human topoisomerase I inhibitors and antitumor agents. Anticancer Agents Med Chem. 2012;12(9):1117–1131.
   PubMed Web of Science ®Google Scholar
• Li PH, Jiang H, Zhang WJ, Li YL, Zhao MC, Zhou W, Zhang LY, Tang YD, Dong CZ, Huang ZS, et al. Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers. Eur J Med Chem. 2018;145:498–510.
   PubMed Web of Science ®Google Scholar
• Witkowska M, Maciejewska N, Ryczkowska M, Olszewski M, Bagiński M, Makowiec S. From tryptophan to novel mitochondria-disruptive agent, synthesis and biological evaluation of 1,2,3,6-tetrasubstituted carbazoles. Eur J Med Chem. 2022;238:114453.
   PubMed Web of Science ®Google Scholar
• Utaipan T, Athipornchai A, Suksamrarn A, Jirachotikoon C, Yuan X, Lertcanawanichakul M, Chunglok W. Carbazole alkaloids from Murraya koenigii trigger apoptosis and autophagic flux inhibition in human oral squamous cell carcinoma cells. J Nat Med. 2017;71(1):158–169.
   PubMed Web of Science ®Google Scholar
• Issa S, Prandina A, Bedel N, Rongved P, Yous S, Le Borgne M, Bouaziz Z. Carbazole scaffolds in cancer therapy: a review from 2012 to 2018. J Enzyme Inhib Med Chem. 2019;34(1):1321–1346.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803.
   PubMed Web of Science ®Google Scholar
• Yoon S, Kim JH, Lee YJ, Ahn MY, Choi G, Kim WK, Yang Z, Lee HJ, Moon HR, Kim HS. A novel carbazole derivative, MHY407, sensitizes cancer cells to doxorubicin-, etoposide-, and radiation treatment via DNA damage. Eur J Pharmacol. 2012;697(1–3):24–31.
   PubMed Web of Science ®Google Scholar
• Bukhari SNA, Ejaz H, Elsherif MA, Junaid K, Zaki I, Masoud RE. Design and synthesis of some new furan-based derivatives and evaluation of in vitro cytotoxic activity. Molecules. 2022;27(8):2606.
   PubMed Web of Science ®Google Scholar
• Abedinifar F, Babazadeh Rezaei E, Biglar M, Larijani B, Hamedifar H, Ansari S, Mahdavi M. Recent strategies in the synthesis of thiophene derivatives: highlights from the 2012–2020 literature. Mol Divers. 2021;25(4):2571–2604.
   PubMed Web of Science ®Google Scholar
• Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JHM. Lapatinib for advanced or metastatic breast cancer. Oncologist. 2012;17(4):536–542.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B. Raltitrexed: current clinical status and future directions. Ann Oncol. 2002;13(4):513–522.
   PubMed Web of Science ®Google Scholar
• Pommier Y, Nussenzweig A, Takeda S, Austin C. Human topoisomerases and their roles in genome stability and organization. Nat Rev Mol Cell Biol. 2022;23(6):407–427.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9(5):338–350.
   PubMed Web of Science ®Google Scholar
• Delgado JL, Hsieh CM, Chan NL, Hiasa H. Topoisomerases as anticancer targets. Biochem J. 2018;475(2):373–398.
   PubMedGoogle Scholar
• Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421–433.
   PubMed Web of Science ®Google Scholar
• Hu W, Huang XS, Wu JF, Yang L, Zheng YT, Shen YM, Li ZY, Li X. Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches. J Med Chem. 2018;61(20):8947–8980.
   PubMed Web of Science ®Google Scholar
• Skok Ž, Zidar N, Kikelj D, Ilaš J. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. J Med Chem. 2020;63(3):884–904.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Escargueil AE, Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol Ther. 2003;99(2):167–181.
   PubMed Web of Science ®Google Scholar
• Oğuztürk E, Tirkeş S, Önal AM. Electrochemical synthesis of new conjugated polymers based on carbazole and furan units. J Electroanal Chem. 2015;750:1–8.
   Web of Science ®Google Scholar
• Damit EF, Nordin N, Ariffin A, Sulaiman K. Synthesis of novel derivatives of carbazole–thiophene, their electronic properties, and computational studies. J Chem. 2016;2016:1–14.
   Web of Science ®Google Scholar
• Lucas I, Germe T, Chevrier-Miller M, Hyrien O. Topoisomerase II can unlink replicating DNA by precatenane removal. EMBO J. 2001;20(22):6509–6519.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Skladanowski A, Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Prog Cell Cycle Res. 1996;2:229–239.
   PubMedGoogle Scholar
• Bergant Loboda K, Janežič M, Štampar M, Žegura B, Filipič M, Perdih A. Substituted 4,5′-bithiazoles as catalytic inhibitors of human DNA topoisomerase IIα. J Chem Inf Model. 2020;60(7):3662–3678.
   PubMed Web of Science ®Google Scholar
• Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23(12):620–633.
   PubMed Web of Science ®Google Scholar
• Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417.
   PubMed Web of Science ®Google Scholar
• Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist. 2006;11(4):342–357.
   PubMed Web of Science ®Google Scholar
• Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents. 2003;3(4):271–290.
   PubMedGoogle Scholar
• Rezonja R, Knez L, Cufer T, Mrhar A. Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions. Radiol Oncol. 2013;47(1):1–13.
   PubMed Web of Science ®Google Scholar
• Mcllwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013;5(4):1–28.
   Web of Science ®Google Scholar
• Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 2006;13(8):1396–1402.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Xu M. DNA fragmentation in apoptosis. Cell Res. 2000;10(3):205–211.
   PubMed Web of Science ®Google Scholar
• Deo SVS, Sharma J, Kumar S. GLOBOCAN 2020 report on global cancer burden: challenges and opportunities for surgical oncologists. Ann Surg Oncol. 2022;29(11):6497–6500.
   PubMed Web of Science ®Google Scholar
• Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.
   PubMed Web of Science ®Google Scholar
• Van Der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834–3848.
   PubMed Web of Science ®Google Scholar
• Pastor N, Domínguez I, Luís Orta M, Campanella C, Mateos S, Cortés F. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012;738–739:45–51.
   PubMed Web of Science ®Google Scholar
• Bau JT, Kang Z, Austin CA, Kurz EU. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform. Mol Pharmacol. 2014;85(2):198–207.
   PubMed Web of Science ®Google Scholar
• Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007;104(26):11014–11019.
   PubMed Web of Science ®Google Scholar
• Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, Adachi N. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008;283(35):23711–23720.
   PubMed Web of Science ®Google Scholar
• Auzanneau C, Montaudon D, Jacquet R, Puyo S, Pouységu L, Deffieux D, Elkaoukabi-Chaibi A, De Giorgi F, Ichas F, Quideau S, et al. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II. Mol Pharmacol. 2012;82(1):134–141.
   PubMed Web of Science ®Google Scholar
• Ortega JA, Arencibia JM, Minniti E, Byl JAW, Franco-Ulloa S, Borgogno M, Genna V, Summa M, Bertozzi SM, Bertorelli R, et al. Novel, potent, and druglike tetrahydroquinazoline inhibitor that is highly selective for human topoisomerase II α over β. J Med Chem. 2020;63(21):12873–12886.
   PubMed Web of Science ®Google Scholar
• Sajewicz W, Dlugosz A. Cytotoxicity of some potential DNA intercalators (carbazole, acridine and anthracene derivatives) evaluated through neutrophil chemiluminescence. J Appl Toxicol. 2000;20(4):305–312.
   PubMed Web of Science ®Google Scholar
• Shaikh MS, Karpoormath R, Thapliyal N, Rane RA, Palkar MB, Faya AM, Patel HM, Alwan WS, Jain K, Hampannavar GA. Current perspective of natural alkaloid carbazole and its derivatives as antitumor agents. Anticancer Agents Med Chem. 2015;15(8):1049–1065.
   PubMed Web of Science ®Google Scholar
• Das A, Mohammed TP, Kumar R, Bhunia S, Sankaralingam M. Carbazole appended trans-dicationic pyridinium porphyrin finds supremacy in DNA binding/photocleavage over a non-carbazolyl analogue. Dalton Trans. 2022;51(33):12453–12466.
   PubMed Web of Science ®Google Scholar
• Ortega JA, Riccardi L, Minniti E, Borgogno M, Arencibia JM, Greco ML, Minarini A, Sissi C, De Vivo M. Pharmacophore hybridization to discover novel topoisomerase II poisons with promising antiproliferative activity. J Med Chem. 2018;61(3):1375–1379.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23(36):9408–9421.
   PubMed Web of Science ®Google Scholar
• Jeon KH, Park S, Jang HJ, Hwang SY, Shrestha A, Lee ES, Kwon Y. Ak-i-190, a new catalytic inhibitor of topoisomerase II with anti-proliferative and pro-apoptotic activity on androgen-negative prostate cancer cells. Int J Mol Sci. 2021;22(20):11246.
   PubMed Web of Science ®Google Scholar
• Kang K, Nho CW, Kim ND, Song DG, Park YG, Kim M, Pan CH, Shin D, Oh SH, Oh HS. Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase. Int J Oncol. 2014;45(2):558–566.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu X, Zou Y, Xing J, Gilson E, Lu Y, Ye J. The topoisomerase II catalytic inhibitor ICRF-193 preferentially targets telomeres that are capped by TRF2. Am J Physiol Cell Physiol. 2015;308(5):C372–C377.
   PubMed Web of Science ®Google Scholar
• Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):87.
   PubMed Web of Science ®Google Scholar
• Kolb RH, Greer PM, Cao PT, Cowan KH, Yan Y. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation. PLOS One. 2012;7(11):e50281.
   PubMed Web of Science ®Google Scholar
• Park SH, Lee J, Kang MA, Jang KY, Kim JR. Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway. Oncol Lett. 2018;15(6):9687.
   PubMed Web of Science ®Google Scholar
• Khélifa T, Beck WT. Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-Jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells. Biochem Pharmacol. 1999;58(8):1247–1257.
   PubMed Web of Science ®Google Scholar
• Iguchi K, Usami Y, Hirano K, Hamatake M, Shibata M, Ishida R. Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs. Biochem Pharmacol. 1999;57(10):1105–1111.
   PubMed Web of Science ®Google Scholar
• Gao W, Zheng M, Li Y. A novel and facile synthesis of 3-(2-benzofuroyl)- and 3,6-bis(2-benzofuroyl)carbazole derivatives. Beilstein J Org Chem. 2011;7:1533–1540.
   PubMed Web of Science ®Google Scholar